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histone demethylases, KDM4C and KDM6A were enzymatically characterized, and subsequently,
four compounds were tested for inhibitory effects. 2,4-dicarboxypyridine and (R)-N-oxalyl-O-ben-
zyltyrosine (3) are both known to bind to a close KDM4C homolog and 3 binds in the part of the cav-
ity that accommodates the side chain in position 11 of histone 3. The inhibition measurements
showed signiﬁcant selectivity between KDM4C and KDM6A. This demonstrates that despite very
similar active site topologies, selectivity between Jumonji family histone demethylases can be
obtained even with small molecule ligands.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The organization of chromatin plays an important role in gene
regulation. The state of chromatin is determined by covalent modi-
ﬁcations of the DNA itself or of the histones that organizes DNA in
the nucleosomes. One such modiﬁcation is methylation of lysines
in the N-terminal regions of in particular histones H3 and H4 [1].
Thesemethylationswere thought to be irreversible until the discov-
ery of lysine speciﬁc demethylase LSD1 [2]. Shortly after, another
family of histone lysine-speciﬁc demethylases (HDMs) was discov-
ered [3]. These enzymes are dioxygenases containing a Jumonji C
(JmjC) domainwith an active site containing Fe(II) and the co-factor
a-ketoglutaric acid.
In 2006, the discovery of the HDM KDM4C, a histone 3 lysine 9
(H3K9) demethylase was published. It was shown that inhibition
of this HDM decreases tumor cell proliferation [4], and the gene
had previously been found to be up regulated in cell lines derived
from esophageal squamous carcinomas [5]. This suggested KDM4Cchemical Societies. Published by E
re of KDM4C; cc6A, catalytic
H, formaldehyde dehydroge-
ine 27; HDM, histone lysine-
nity chromatography; JmjC,
ltyrosine; 3, (R)-N-oxalyl-O-
sion chromatographyto be an oncogene, thus making the development of inhibitors an
important issue. A number of inhibitors against KDM4C and the
closely related KDM4A and KDM4E have recently been disclosed
[6–9], and the binding mode of a number of them have been estab-
lished, since 3D structures are available of the catalytic cores (cc) of
KDM4A [10], KDM4C (PDB code 2XML, unpublished) and KDM4D
(PDB code 3DXT, unpublished).
In 2007, the histone 3 lysine 27 (H3K27) speciﬁc HDM denoted
KDM6A was discovered, and shown to be important for the regula-
tion of HOX genes that are central during cellular differentiation
[11]. Results accumulated during the later years suggest that
KDM6A acts as a tumor repressor [12–15]. Thus, in terms of the po-
tential of JmjC HDM inhibitors as anti-cancer agents, it appears cru-
cial that inhibitors targeting KDM4C do not affect KDM6A function
andactivity. The3Dstructure ofKDM6A is currentlyunknown,how-
ever, the structure of the cc of the closely related KDM6B has re-
cently been deposited in PDB (PDB code 2XXZ, unpublished). This
enables structural comparison as a tool to identify differences in
the active site architecture and, through this comparison, to obtain
inhibitors that display selectivity between KDM4C and KDM6A.
Using the oncogenic KDM4C and tumor repressor protein
KDM6A as model system, we show that selective inhibition of
KDM4C by small molecule inhibitors is achievable. Furthermore,
we demonstrate that inhibition of KDM4C by targeting of the
speciﬁc part of the active site accommodating position 11 of the his-
tone 3 peptide substrate, based on a strategy described elsewherelsevier B.V. All rights reserved.
Fig. 1. Synthesis of compounds 1–3 from (R)-tyrosine. (a) SOCl2, CH3OH, reﬂux, 4 h;
(b) monomethyl oxalylchloride, toluene, reﬂux, 4 h; (c) 1 M NaOH, r.t., 2 h, then ion-
exchange; (d) CuSO4, NaOH, benzylbromide, H2O/CH3OH, r.t., 16 h, and then
neutralization.
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the kinetic characterizations of these proteins have not been re-
ported, we present the kinetic characterization of the catalytic cores
of KDM4C (cc4C) andKDM6A (cc6A). Based on the kinetic character-
izations, we identify H3 peptide substrates suitable for screening
purposes and utilize these to identify KDM4C selective inhibitors.
2. Materials and methods
2.1. General
All chemicals used for buffers, co-factors, lysozyme, DNAse,
formaldehyde dehydrogenase (FDH) from Pseudomonas putida,
N-oxalylglycine (NOG), 2,4-dicarboxypyridine (2,4-DCP), a-cyano-Fig. 2. Enzyme kinetic plots of 25 lM cc6A for synthetic 24- and 15-meric H3K27me3
(lM formed NADHmin1) as a function of concentration of peptide substrate in lM. (A) T
the 15-meric peptide substrate at cc6A. (C) The kinetic proﬁle of the 8-meric peptide sub
cooperativity observed for the 24-meric HeK27me3 substrate. Error bars represent one4-hydroxy cinnamic acid and polystyrene NBS™ treated 384 wells
plates used for FDH assay were from Sigma–Aldrich, Denmark. Sol-
vents for MALDI-TOF were of HPLC-grade and from Merck, Den-
mark. EDTA free protease inhibitor cocktail tablets used in
protein puriﬁcation were from Roche. Histone tail H3K9me3 and
H3K27me3 synthetic peptide substrates were purchased from Pep-
tide 2.0, USA or generously donated by Novo Nordisk A/S, Den-
mark. The plasmid coding for cc4C (1–349) was generously
donated by the Biotech Research and Innovation Center (BRIC),
Denmark. The pOPIN vector F was generously donated by the Ox-
ford Protein Production Facility, Great Britain. All reagents and sol-
vents for the synthesis of (R)-N-oxalyl-tyrosine (1) and (R)-N-
oxalyl-O-benzyltyrosine (3) were purchased from Sigma–Aldrich,
Denmark or VWR, Denmark and used without further puriﬁcation.
NMR spectra were recorded on a 300 MHz Varian spectrometer at
room temperature (r.t.). Elemental analysis was performed at the
University of Vienna, Austria. Melting points were determined in
an open capillary tube and are uncorrected.
2.2. Cloning, expression and puriﬁcation of cc4C and cc6A
The detailed procedures are supplied in Supplementary infor-
mation. In summary, the N-terminal His-tagged proteins were ex-
pressed in Escherichia coli using auto-induction [16] and puriﬁed
by immobilized metal afﬁnity chromatography (IMAC) and size
exclusion chromatography (SEC).
2.3. Synthesis of compounds 1–3
Compounds 1 and 3 were both synthesized starting from (R)-
tyrosine (Fig. 1). O-Benzylation of (R)-tyrosine to produce (R)-O-
benzyltyrosine (2) was done similar to the procedure of Otake
and Izawa [17]. The N-oxalyl amino acids, 1 and 3, were producedsubstrates and 2.5 lM cc4C for 8-meric H3K9me3 substrate. Initial velocity (V0)
he kinetic proﬁle of the 24-meric peptide substrate at cc6A. (B) The kinetic proﬁle of
strate at cc4C. Corresponding Hill plots have been inserted to illustrate the negative
standard deviation (S.D.).
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is stated in Supplementary information.
2.4. Enzyme kinetics and inhibition studies
For determination of enzyme kinetics and inhibition studies of
cc4C and cc6A, a FDH coupled assay was set up, essentially as de-
scribed elsewhere [19]. Experiments were carried out in 384 wells,
low volume, ﬂat bottomed solid black NBS™ surface treated poly-
styrene plates (Corning) and on the same batch of protein. Assay
buffer consisted of 50 mM HEPES, pH 7.5, 50 mM NaCl, 500 lM
a-ketoglutaric acid, 0.5–5 mM ascorbate, 2 mM NAD+, 0.05–0.5 U
FDH and 50–500 lM Fe(II). Assays were carried out in triplicate
measurements in 10% DMSO at 37 C and the total reaction volume
was 25 ll. For the determination of kinetics parameters, 2.5 lM
cc4C was incubated with 8-meric H3(7–14)K9me3 peptide
substrate ARK(me3)STGGK (7.8–500 lM) and 25 lM cc6A was
incubated with 24-meric H3(21–44)K27me3 ATKAARK(me3)SAPA-
TGGVKKPHRYRPG (5–2000 lM), 15-meric H3(20–34)K27me3
LATKAARK(me3)SAPATGG (5–2000 lM) and 9-meric H3(23–
31)K27me3 KAARK(me3)SAPA (5–2000 lM) substrates. For
inhibition studies, 5 lM cc4C and 12.5 lM cc6A were incubated
for 30 min with various concentrations of ligands before adding
100 lM of H3K9me3 in the case of cc4C and 500 lM H3K27me3
in the case of cc6A. The formation of NADH, measured as
an increase in relative ﬂuorescence units, were monitored with a
Saﬁre2™ microplate reader (Tecan) in 30 s cycles over a
period of minimum 15 min (up to 24 h) and converted to
lMNADH formed min1 using a NADH standard curve (Supple-
mentary Fig. S1). Excitation wavelength and emission wavelength
was 355 nm and 460 nm, respectively. For inhibition studies, the
8-meric cc4C (100 lM) and 15-meric cc6A (500 lM) substrates
were used. Reaction mixtures of assay buffer without substrate
were used as negative controls. For curve ﬁtting and data analysis,
GraphPad Prism 5.0 was used.2.5. MALDI-TOF
The enzymatic reaction was carried out as described and
quenched by addition of 50% (v/v) of 1% TFA. The reaction mixture
was diluted 1:9with a saturated solution of a-cyano-4-hydroxycin-
namic acid in 65% acetonitrile, in MilliQ water containing 0.1% TFA.
Onemilliliter was spotted onto the target and air dried for 15 min at
r.t. TheMALDI-TOFMSwas carriedout onanUltraﬂexTOF/TOF (Bru-
ker) operated in positive ion mode with an ion source voltage of
25 kV, a lens voltage of 7.5 kV and a reﬂector voltage of 26.3 kV.
The system was run in deﬂection mode with a mass suppression of
500 Da. The data analysis was carried out using the FlexAnalysis
software (Bruker). Baseline subtraction and smoothing of the curves
was applied.Table 1
Kprime/Km, kcat and kcat/Km values of cc6A and cc4C for various H3K27me3 and H3K9me3 pep
for each value. Note that for the 24-meric peptide substrate, a Kprime value is listed instead o
or MALDI-TOF MS.
Substrate Enzyme Kprime/Km (l
H3(21–44)K27me3 24-meric cc6A 139.5 ± 15.
H3(20–34)K27me3 15-meric cc6A 495.4 ± 34.
H3(23–31)K27me3 9-meric cc6A N.D
H3(7–14)K9me3 8-meric cc4C 23.9 ± 3.9
Enzyme Ligands NOG
cc6A IC50 (lM) 531 ± 14
cc4C IC50 (lM) 681 ± 142.6. GRID analysis
The GRID program version 22 [20] was used to characterize the
binding pockets of cc4A and cc6B using the C3 probe.3. Results and discussion
3.1. The ccs of KDM4C and KDM6A
Approximately 2 mg of puriﬁed cc4C (1–349) and cc6A (940–
1401) was obtained pr. liter expression media. Initial protein pur-
ity after IMAC puriﬁcations were approximately 60–75%. The pro-
tein purity after SEC was higher than 90% as assessed by SDS–PAGE
(Supplementary Fig. S2).
3.2. Enzyme kinetics of cc4C and cc6A
To identify histone 3 peptide substrates suitable for screening
purposes, a series of H3K27me3 peptides were tested. The results
show that different cc6A peptide substrates resulted in different ki-
netic proﬁles. The 24-meric H3K27me3 substrate exhibited a nega-
tive cooperativekinetic proﬁlewith aHill slope of 0.64,while the15-
meric substrate exhibited Michaelis–Menten kinetics (Fig. 2). Turn-
over of a shorter (9-meric) peptidewas not detected by FDH assay or
by MALDI-TOF. Based on the kinetic studies, the 15-meric peptide
substrate was chosen for inhibition studies. With regard to cc4C,
only an 8-meric peptide was tested, since this substrate has fre-
quently been used in cc4A, cc4C and cc4E inhibition studies [7,8].
This substrate also exhibited Michaelis–Menten kinetics (Fig. 2).
Various concentrations of Fe(II) (50–500 lM) and FDH (0.05–
0.5 U) did not alter the turnover of peptide substrates. The kinetic
parametersKprime/Km, kcatand kcat/Kmof cc6Aandcc4C for thevarious
peptide substrates are summarized in Table 1. The difference in Km/
Kprime and Kcat indicates that the 15-meric substratemay have a low-
er binding afﬁnity, but a higher turnover. However, comparison of
the substrate speciﬁcity constants (kcat/Km values) reveals that
cc6A demethylates the 24-meric substrate approximately 2.5-fold
more efﬁciently than the 15-meric substrate. Also, the kinetics re-
vealed that KDM4C is a more efﬁcient enzyme than KDM6A, when
comparing the substrate speciﬁcity constants. General enzymatic
activitywas conﬁrmedbyMALDI-TOFMS. TheH3K27me3cc6A sub-
strates were primarily demethylated to H3K27me2, but in case of
the 24-meric substrate also to trace amounts of the monomethylat-
ed species (Supplementary Fig. S3). This correlates with previous
ﬁndings for full length KDM6A incubated with core histones
[11,21]. An 8-meric H3K9me3 cc4C substrate was primarily
demethylated to H3K9me2 but also to themonomethylated species
(Supplementary Fig. S3). This observation is in agreement with pre-
vious ﬁndings for the full length protein, in which a 40-meric
synthetic substrate and core histones were used [4].tide substrates. In addition, IC50 values of four inhibitors are given. One S.D. is reported
f a Km value, due to negative cooperativity. N.D: Not detectable by FDH-coupled assay
M) kcat (min1) kcat/Km (min1 lM1  103)
1 0.19 ± 0.04 1.36 ± 0.29
7 0.29 ± 0.01 0.58 ± 0.05
N.D N.D
0.37 ± 0.06 15.5 ± 3.5
2,4-DCP 1 3
177 ± 12 1000 625
2.4 ± 0.1 281 ± 15 135 ± 16
Fig. 3. Inhibition data of compound 3 at cc4C and representative MALDI-TOF MS spectra. (A) IC50 curve of 3. (B–E) MALDI-TOF MS spectra of 100 lM 8-meric peptide
incubated with: (B) reaction buffer (negative control); (C) 5 lM cc4C; (D) 5 lM cc4C and 78 lM 3; (E) 5 lM cc4C and 1.25 mM 3. All intensities are in relative units. The
additional top at approximately 854 in (C–E) is a me2, Na adduct. Error bars represent one S.D.
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For inhibitionstudies, the four compounds,NOG,2,4-DCP,1and3
were tested (Table 1). In the case of cc4C, all four tested ligands have
inhibitory effect, in agreementwith previous ﬁndings for cc4A, cc4C
and cc4E [7–9]. NOG, the inactive amide analog of a-ketoglutaric
acid, inhibited both cc4C and cc6Awith comparable IC50 values, sug-
gesting the samebindingmodeof NOG to cc4C and cc6A. In contrast,
the IC50 of 2,4-DCP was almost a factor 75 higher for cc6A (177 lM)
than for cc4C (2.4 lM), demonstrating subtype selectivity. This dif-
ference in afﬁnitymay be explained by structural comparison of the
crystal structures of cc4A with 2,4-DCP bound [7] and cc6B (PDB
code 2XXZ, unpublished), a close homolog to cc6A (84% sequence
similarity of the cc region [21]). In cc4A (and cc4C), Lys241 interacts
with the carboxylic group in position 2 of 2,4-DCP (Fig. 4C). In cc6A
and cc6B, Lys241 corresponds toAsp1440. Furthermore, this residue
is positioned away from the cc, due to differences in a backbone loop
(Fig. 4C), causing a loss of interaction thatmost likely causes a signif-
icant decrease in afﬁnity, as observed.
Compounds 1 and 3 inhibited cc4C in the lM range (281 and
135 lM, respectively). It has previously been shown that 3 is aKDM4 selective inhibitor, when compared to factor-inhibiting hy-
poxia-inducible factor, another JmjC containing dioxygenase
[8,22]. Similarly, we observed no inhibition of cc6A at 625 lM,
indicating selectivity of 3 towards KDM4C compared to KDM6A.
For compound 3, an IC50 curve and representative MALDI-TOF
MS spectra for the inhibition of KDM4C are shown in Fig. 3. Com-
parison of the structures of cc4A (in complex with 3 (PDB code
2WWJ), NOG and an 8-meric H3K9me3 substrate (PDB code
2OQ6)) and cc6B (PDB code 2XXZ), shows that the amino acids sur-
rounding 3 are different in cc4A (and cc4C) compared to cc6B (and
cc6A). For example, in the crystal structure of cc4A (Fig. 4A), 3
makes favorable van der Waals interactions with the surrounding
amino acids, with the benzyloxy phenyl group of 3 occupying posi-
tion 11 of the substrate [8]. In the cc6B structure, 3 does not ﬁt well
into the pocket (Fig. 4B), when superimposing it to cc4A. Moreover,
in cc4A, a weak hydrogen bond between the oxygen atom of 3 and
the backbone amide nitrogen of Ala186 was reported [8]. This
interaction is not possible in cc6B and presumably also not in
cc6A, because Ala186 (cc4A) corresponds to Pro1385 (cc6B).
Taken together, we have shown that selective inhibition of cc4C,
in the low lM range, by small molecule ligands is achievable.
Fig. 4. Structural comparison of cc4A and cc6B. (A) Crystal structure of cc4A (PDB code 2WWJ [8]) in complex with 3 (cyan C atoms). (B) Crystal structure of cc6B (PDB code
2XXZ) superimposed with 2WWJ. (C) Ribbon representation of the crystal structure of cc4A in complex with 2,4-DCP (cyan C atoms) superimposed with 2XXZ. Gray surface
shows isosurface at 0.1 kcal/mol of the C3 probe, indicating favorable vdW interactions.
J.B.L. Kristensen et al. / FEBS Letters 585 (2011) 1951–1956 1955However, optimization of the scaffolds is necessary for the devel-
opment of new inhibitors exhibiting high afﬁnity and selectivity
towards the KDM4 HDM subtypes. Such inhibitors may provide a
new strategy for future cancer treatment.
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